Pfizer's (PFE) much-hyped Tofacitnib rheumatory arthritis treatment isn't necessarily a...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer's (PFE) much-hyped Tofacitnib rheumatory arthritis treatment isn't necessarily a sure-fire winner, according to a recent survey of doctors and payers. 55% of the doctors responding say that the Pfizer pill wouldn't replace a med they are currently prescribing, while 96% of payers indicate the pill wouldn't replace a drug that is currently offered in their plans.